All In Biotech

Drug Trial Radar · NCT02910219

Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients

Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients Receiving Trastuzumab, Pertuzumab, and Docetaxel or Paclitaxel With or Without Carboplatin: HALT-D

Last checked: Nov 20, 2026Latest source record: Oct 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

53

Actual

Start

Jan 31, 2017

Primary completion

Nov 23, 2020

Study completion Nov 23, 2020

Sponsor

Lead sponsor
Sandra SwainAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Lombardi Comprehensive Cancer Center; Medstar Health Research Institute; Genentech, Inc.; Napo Pharmaceuticals, Inc.
First posted
Sep 21, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Chemotherapy induced diarrhea is seen in up to 40-80% of patients receiving this treatment for HER2 positive locally advanced or metastatic breast cancer. This diarrhea can significantly impact a patient's quality of life and ability to tolerate chemo/anti-HER2 therapy. This study will look at the efficacy of the drug crofelemer in preventing diarrhea in breast cancer patients.

Conditions

  • Breast Cancer

Interventions

  • CrofelemerDrug

    Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Diarrhea for >= 2 Consecutive DaysTime frame: Cycle 1, Cycle 2 (each cycle is 21 days)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia

  • MedStar Franklin Square Cancer Center at Loch Raven Campus

    Baltimore, Maryland

  • Harry and Jeanette Weinberg Cancer Institute

    Baltimore, Maryland

  • John Theurer Cancer Center at Hackensack Univ

    Hackensack, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.